• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

急诊科丁丙诺啡起始治疗的促进因素和障碍:一项范围综述

Facilitators of and barriers to buprenorphine initiation in the emergency department: a scoping review.

作者信息

Bozinoff Nikki, Grennell Erin, Soobiah Charlene, Farhan Zahraa, Rodak Terri, Bucago Christine, Kingston Katie, Klaiman Michelle, Poynter Brittany, Shelton Dominick, Schoenfeld Elizabeth, Kalocsai Csilla

机构信息

Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, 1001 Queen Street W, Toronto, Ontario, Canada.

Department of Family and Community Medicine, University of Toronto, 500 University Avenue, Toronto, Ontario, Canada.

出版信息

Lancet Reg Health Am. 2024 Sep 28;38:100899. doi: 10.1016/j.lana.2024.100899. eCollection 2024 Oct.

DOI:10.1016/j.lana.2024.100899
PMID:39381082
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11459582/
Abstract

Buprenorphine initiation in the Emergency Department (ED) has been hailed as an evidence-based strategy to mitigate the opioid overdose crisis, but its implementation has been limited. This scoping review synthesizes barriers and facilitators to buprenorphine initiation in the ED, and uses the Consolidated Framework for Implementation Research and a critical lens to analyze the literature. Results demonstrate an immense effort across the U.S. and Canada to implement ED-initiated buprenorphine. Facilitators include multidisciplinary addiction teams and co-located, low-barrier, harm reduction-informed services to support transitions. Barriers include a failure to address structural stigma, client complexity, and an increasingly toxic drug supply. The literature also misses the opportunity to include the perspectives of service users, health administrators, and learners. Increased coordination of implementation efforts, and a shift to equitable and inclusive opioid agonist therapy initiation pathways are needed across the U.S. and Canada.

摘要

在急诊科启动丁丙诺啡被视为缓解阿片类药物过量危机的一项循证策略,但其实施情况有限。本范围综述总结了急诊科启动丁丙诺啡的障碍和促进因素,并运用实施研究综合框架和批判性视角对文献进行分析。结果表明,美国和加拿大为实施急诊科启动丁丙诺啡付出了巨大努力。促进因素包括多学科成瘾治疗团队以及共同选址、低门槛、基于减少伤害理念的服务以支持转诊。障碍包括未能消除结构性污名、服务对象情况复杂以及药物供应毒性日益增加。文献还未纳入服务使用者、卫生管理人员和学习者的观点。美国和加拿大都需要加强实施工作的协调,并转向公平和包容的阿片类激动剂治疗启动途径。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6f7/11459582/a2f0c04e18be/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6f7/11459582/b5a180a5459a/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6f7/11459582/15002abdb5a9/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6f7/11459582/a2f0c04e18be/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6f7/11459582/b5a180a5459a/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6f7/11459582/15002abdb5a9/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6f7/11459582/a2f0c04e18be/gr3.jpg

相似文献

1
Facilitators of and barriers to buprenorphine initiation in the emergency department: a scoping review.急诊科丁丙诺啡起始治疗的促进因素和障碍:一项范围综述
Lancet Reg Health Am. 2024 Sep 28;38:100899. doi: 10.1016/j.lana.2024.100899. eCollection 2024 Oct.
2
Facilitators of and barriers to buprenorphine initiation for people with opioid use disorder in the emergency department: protocol for a scoping review.在急诊科为患有阿片类药物使用障碍的人启动丁丙诺啡的促进因素和障碍:系统评价方案。
BMJ Open. 2021 Sep 27;11(9):e053207. doi: 10.1136/bmjopen-2021-053207.
3
Implementation of a rural emergency department-initiated buprenorphine program in the mountain west: a study protocol.农村急诊科发起丁丙诺啡项目的实施:一项研究方案。
Addict Sci Clin Pract. 2024 Sep 3;19(1):63. doi: 10.1186/s13722-024-00496-0.
4
Barriers and facilitators to buprenorphine use for opioid agonist treatment: protocol for a scoping review.阿片类激动剂治疗中丁丙诺啡使用的障碍和促进因素:系统评价方案。
BMJ Open. 2019 Dec 15;9(12):e032285. doi: 10.1136/bmjopen-2019-032285.
5
Emergency department interventions for opioid use disorder: A synthesis of emerging models.急诊科干预阿片类药物使用障碍:新兴模式的综合。
J Subst Abuse Treat. 2022 Oct;141:108837. doi: 10.1016/j.jsat.2022.108837. Epub 2022 Jul 11.
6
Implementation facilitation to promote emergency department-initiated buprenorphine for opioid use disorder: protocol for a hybrid type III effectiveness-implementation study (Project ED HEALTH).促进急诊科启动丁丙诺啡治疗阿片类药物使用障碍的实施促进:一项混合 III 型有效性实施研究(项目 ED HEALTH)的方案。
Implement Sci. 2019 May 7;14(1):48. doi: 10.1186/s13012-019-0891-5.
7
Barriers and Facilitators to Clinician Readiness to Provide Emergency Department-Initiated Buprenorphine.临床医生准备在急诊科提供丁丙诺啡的障碍和促进因素。
JAMA Netw Open. 2020 May 1;3(5):e204561. doi: 10.1001/jamanetworkopen.2020.4561.
8
Barriers and facilitators associated with establishment of emergency department-initiated buprenorphine for opioid use disorder in rural Maine.缅因州农村地区急诊科启动丁丙诺啡治疗阿片类物质使用障碍的相关障碍与促进因素
J Rural Health. 2022 Jun;38(3):612-619. doi: 10.1111/jrh.12617. Epub 2021 Sep 1.
9
Barriers and facilitators to safer supply pilot program implementation in Canada: a qualitative assessment of service provider perspectives.加拿大更安全供应试点项目实施的障碍与促进因素:对服务提供者观点的定性评估
Harm Reduct J. 2025 Apr 28;22(1):68. doi: 10.1186/s12954-025-01177-0.
10
Healthcare provider perspectives on emergency department-initiated buprenorphine/naloxone: a qualitative study.医疗机构对急诊处开出的丁丙诺啡/纳洛酮的看法:一项定性研究。
BMC Health Serv Res. 2024 Feb 15;24(1):211. doi: 10.1186/s12913-023-10271-7.

引用本文的文献

1
Assessing inequities in buprenorphine treatment across the care cascade.评估丁丙诺啡治疗在整个照护流程中的不公平性。
Drug Alcohol Depend. 2025 May 1;270:112636. doi: 10.1016/j.drugalcdep.2025.112636. Epub 2025 Feb 28.
2
Preliminary PUPPYS: An Objective Clinical Assessment Tool to Measure Opioid Withdrawal in the Emergency Department.初步的PUPPYS:一种用于急诊科测量阿片类药物戒断反应的客观临床评估工具。
J Med Toxicol. 2025 Apr;21(2):284-286. doi: 10.1007/s13181-024-01056-3. Epub 2025 Feb 5.

本文引用的文献

1
Initiation of opioid agonist therapy after hospital visits for opioid poisonings in Ontario.安大略省因阿片类药物中毒住院后开始使用阿片类激动剂治疗。
CMAJ. 2023 Dec 17;195(49):E1709-E1717. doi: 10.1503/cmaj.231014.
2
A conceptual framework for how structural changes in emerging acute substance use service models can reduce stigma of medications for opioid use disorder.一个关于新兴急性物质使用服务模式中的结构变化如何减少阿片类药物使用障碍药物污名化现象的概念框架。
Front Psychiatry. 2023 Sep 27;14:1184951. doi: 10.3389/fpsyt.2023.1184951. eCollection 2023.
3
National Institute on Drug Abuse Clinical Trials Network Meeting Report: Advancing Emergency Department Initiation of Buprenorphine for Opioid Use Disorder.
国家药物滥用研究所临床试验网络会议报告:推进急诊科阿片类药物使用障碍丁丙诺啡的使用。
Ann Emerg Med. 2023 Sep;82(3):326-335. doi: 10.1016/j.annemergmed.2023.03.025. Epub 2023 May 12.
4
Addressing buprenorphine bottlenecks in the context of MAT Act implementation: A shared responsibility.在《药物辅助治疗法案》实施背景下解决丁丙诺啡瓶颈问题:一项共同责任。
J Am Pharm Assoc (2003). 2023 Jul-Aug;63(4):1044-1048. doi: 10.1016/j.japh.2023.04.029. Epub 2023 May 4.
5
The Impact of Suboxone's Market Exclusivity on Cost of Opioid Use Disorder Treatment.丁丙诺啡的市场专有权对阿片类药物使用障碍治疗费用的影响。
Appl Health Econ Health Policy. 2023 May;21(3):501-510. doi: 10.1007/s40258-022-00787-0. Epub 2023 Jan 18.
6
An evaluation of the association between specific post-overdose care services in emergency departments and subsequent treatment engagement.对急诊科特定过量用药后护理服务与后续治疗参与之间关联的评估。
J Am Coll Emerg Physicians Open. 2023 Jan 11;4(1):e12877. doi: 10.1002/emp2.12877. eCollection 2023 Feb.
7
The updated Consolidated Framework for Implementation Research based on user feedback.基于用户反馈的更新的实施研究综合框架。
Implement Sci. 2022 Oct 29;17(1):75. doi: 10.1186/s13012-022-01245-0.
8
Analysis of US County Characteristics and Clinicians With Waivers to Prescribe Buprenorphine After Changes in Federal Education Requirements.联邦教育要求变更后美国县特征及获得开具丁丙诺啡豁免权的临床医生分析。
JAMA Netw Open. 2022 Oct 3;5(10):e2237912. doi: 10.1001/jamanetworkopen.2022.37912.
9
Recommendations for the extraction, analysis, and presentation of results in scoping reviews.综述的提取、分析和结果呈现建议。
JBI Evid Synth. 2023 Mar 1;21(3):520-532. doi: 10.11124/JBIES-22-00123.
10
Education as drug policy: A realist synthesis of continuing professional development for opioid agonist therapy.作为毒品政策的教育:阿片类激动剂治疗持续专业发展的实在论综合分析
Int J Drug Policy. 2022 Oct;108:103807. doi: 10.1016/j.drugpo.2022.103807. Epub 2022 Aug 2.